Literature DB >> 8471415

The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.

E Skjelbo1, L F Gram, K Brøsen.   

Abstract

The metabolism of imipramine was investigated in 106 healthy volunteers, all having a sparteine metabolic ratio (MR) of 0.2-0.5 and hence classified as extensive metabolisers. Each subject was given a single oral dose of 25 mg imipramine hydrochloride and blood for assays of imipramine and metabolites was collected 3 h thereafter. The desipramine/imipramine ratio and the 2-OH-desipramine/2-OH-imipramine ratio in plasma, reflecting the demethylation of imipramine and 2-OH-imipramine, respectively, showed significant negative correlations with the mephenytoin S/R ratio (Spearman rank correlation) (rs): -0.46, P < 0.00002 and -0.41, P < 0.00002). No correlations were found between the 2-hydroxylation of imipramine or desipramine and the mephenytoin S/R. These findings confirm those of an earlier panel study showing that the demethylation of imipramine and 2-OH-imipramine cosegregates in part with the mephenytoin oxidation polymorphism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471415      PMCID: PMC1381588     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.

Authors:  S A Ward; T Walle; U K Walle; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

Review 2.  Plasma level monitoring of tricyclic antidepressant therapy.

Authors:  L F Gram
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase.

Authors:  C Ged; D R Umbenhauer; T M Bellew; R W Bork; P K Srivastava; N Shinriki; R S Lloyd; F P Guengerich
Journal:  Biochemistry       Date:  1988-09-06       Impact factor: 3.162

4.  Prediction of steady-state behavior of metabolite from dosing of parent drug.

Authors:  E A Lane; R H Levy
Journal:  J Pharm Sci       Date:  1980-05       Impact factor: 3.534

5.  Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1986-11       Impact factor: 6.875

6.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Imipramine metabolites in blood of patients during therapy and after overdose.

Authors:  L F Gram; M Bjerre; P Kragh-Sørensen; B Kvinesdal; J Molin; O L Pedersen; N Reisby
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

8.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Authors:  S A Ward; N A Helsby; E Skjelbo; K Brøsen; L F Gram; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

9.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.

Authors:  P Baumann; M Jonzier-Perey; L Koeb; A Küpfer; D Tinguely; J Schöpf
Journal:  Int Clin Psychopharmacol       Date:  1986-04       Impact factor: 1.659

View more
  5 in total

1.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

Authors:  H Madsen; K K Nielsen; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 2.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

Authors:  K Chiba; A Saitoh; E Koyama; M Tani; M Hayashi; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.